NCT06897605RecruitingPhase 2
Impact of Dapagliflozin in Anemic Chronic Kidney Disease Patients
Clinical Study Evaluating the Impact of Dapagliflozin on Erythropoiesis-Stimulating Agent Responsiveness in Anemic Patients With Chronic Kidney Disease
Source: ClinicalTrials.gov · Last updated 2 Apr 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Dapagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor, primarily used in the management of type 2 diabetes mellitus. Emerging research suggests that SGLT2 inhibitors may offer additional benefits, including reducing the risk of cardiovascular events and renal complications. Post hoc analyses of previous clinical trials have shown that patients treated with SGLT2 inhibitors exhibited higher levels of hemoglobin and hematocrit compared to those in the control group. These findings suggest that dapagliflozin's ability to elevate hemoglobin levels could potentially be utilized for the treatment of anemia in patients with chronic kidney disease.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 80 (estimated)
- First submitted
- 20 Mar 2025
- Start date
- 1 Apr 2025
- Primary completion date
- Oct 2025
- Lead sponsor
- Mansoura University
- Diseases
- Chronic kidney disease
- NCT number
- NCT06897605
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 80
- From 1 Apr 2025 to the primary completion date, Oct 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients with acute heart failure, acute myocardial infarction, or stroke occurring within 6 months before enrollment in the trial.
Other illness
- Anemia due to causes other than chronic kidney disease, such as pernicious anemia, thalassemia, sickle cell anemia, or myelodysplastic syndromes.
- Patients with severe ketosis, diabetic coma, severe infection, perioperative complications, or severe trauma.
- Patients with current malignancies or a history of malignancy within the past 2 years.
- Patients with severe gastrointestinal bleeding.
Other
- Diagnosed with pure red cell aplasia.
- Pregnant or lactating females.
Who the study is looking for
- Adults aged ≥ 18 years with CKD stage III or IV.
- Patients with anemia of CKD and a hemoglobin level \< 11.5 g/dL
- Patients are receiving erythropoiesis-stimulating agent therapy.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Urology and Nephrology Center Coordinator of this site? Confirm its status | Al Mansurah | Egypt | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.